Setanaxib

Small molecule

Also known as GKT137831

Phase 2topline reported

Evidence outlook

Primary Biliary Cholangitis: topline reported 2024-07-26

The sponsor reported topline results on 2024-07-26 (Phase 2b TRANSFORM of setanaxib in PBC met its primary endpoint (ALP reduction versus placebo)). The announcement is listed under Regulatory events.

Latest reported trial: TRANSFORM (NCT05014672) · Phase 2 · met primary endpoint · grade pending

Featured evidence outside this drug's tracked markets:NCT06274489 · Alport Syndrome · Phase 1/2 · completed · Weak signal

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 2 (5)
Primary Biliary Cholangitis
NCT03226067 · Calliditas Therapeutics AB
2017-06-26 – 2019-04-11 · Primary Biliary Cirrhosis
What this study did
Other / comorbidity
NCT05323656 · Calliditas Therapeutics Suisse SA
2022-04-06 – 2025-08-21 · Squamous Cell Carcinoma of Head and Neck
What this study did
NCT02010242 · Calliditas Therapeutics AB
2013-10 – 2015-03 · Type 2 Diabetes Mellitus With Diabetic Nephropathy
What this study did
Phase 1/2 (1)
Other / comorbidity
NCT06274489 · Calliditas Therapeutics AB
2023-11-27 – 2025-06-25 · Alport Syndrome
What this study did
Phase 1 (2)
Other / comorbidity
NCT04327089 · Calliditas Therapeutics AB
2020-06-24 – 2021-03-23 · Phase 1
What this study did
NCT03740217 · Calliditas Therapeutics AB
2018-12-19 – 2019-02-06 · Phase 1
What this study did

Competitive landscape

This drug's own stage for Primary Biliary Cholangitis: Phase 2. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Setanaxib: this drugPhase 2Small moleculeNOX1/4not yet gradedNo reviewed efficacy summary in this indication
Elafibranor (Iqirvo)ApprovedSmall moleculePPAR-alpha/PPAR-deltaPartial signal
NCT04526665: Percentage of Participants With Response to Treatment Based on Cholestasis Response at Week 52 (At Week 52): Elafibranor 80 mg 50.9 Percentage of participants (95% CI 41.6 to 60.2) | Placebo 3.8 Percentage of participants (95% CI 1 to 12.8)
Seladelpar (Livdelzi)ApprovedSmall moleculePPAR-deltaPartial signal
NCT06060665: Primary endpoint, composite ALP normalization at week 52: significantly more patients than placebo (Gilead, 2026-06-02).
NCT04620733: Composite biochemical response at Month 12 (ALP below 1.67 x ULN, ALP reduction of at least 15% and total bilirubin at or below ULN), seladelpar (n=128) vs placebo (n=65): 61.7% vs 20.0%; risk difference 41.7 percentage points (95% CI 27.7 to 53.4), p < 0.0001 (Cochran-Mantel-Haenszel; CT.gov posted results).
Saroglitazar (Lipaglyn)Phase 3Small moleculePPAR-alpha/PPAR-gammaPartial signal
NCT05133336: Primary composite biochemical response at 52 weeks: treatment difference 48.5% favouring saroglitazar 1 mg over placebo (P<0.001) (2025-08-29).
Pemafibrate (Parmodia)Phase 2Small moleculePPAR-alphanot yet gradedNo reviewed efficacy summary in this indication
VolixibatPhase 2Small moleculeIleal bile acid transporter (IBAT)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

No upcoming readouts on record for this asset.

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

26 July 2024Topline resultPhase 2b TRANSFORM of setanaxib in PBC met its primary endpoint (ALP reduction versus placebo)
Calliditas Therapeutics AB · Source ↗